VISTA (protein)

 V-domain Ig suppressor of T cell activation (VISTA) is a type I transmembrane protein that functions as an immune checkpoint and is encoded by the C10orf54 gene.[5][6][7]

VSIR
Identifiers
AliasesVSIR, B7-H5, B7H5, GI24, PP2135, SISP1, DD1alpha, VISTA, C10orf54, chromosome 10 open reading frame 54, PD-1H, V-set immunoregulatory receptor, Dies1
External IDsOMIM615608 MGI1921298 HomoloGene81923 GeneCardsVSIR
Gene location (Human)
Chromosome 10 (human)
Chr.Chromosome 10 (human)[1]
Chromosome 10 (human)
Genomic location for VSIR
Genomic location for VSIR
Band10q22.1Start71,747,556 bp[1]
End71,773,520 bp[1]
RNA expression pattern
PBB GE C10orf54 gnf1h08188 s at fs.png
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_022153

NM_001159572
NM_028732

RefSeq (protein)

NP_071436

NP_001153044
NP_083008

Location (UCSC)Chr 10: 71.75 – 71.77 MbChr 10: 60.35 – 60.37 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Structure and functionEdit

VISTA is approximately 50kDa and belongs to the immunoglobulin superfamily and has one IgV domain.[8][5]

VISTA is part of the B7 family, is primarily expressed in white blood cells and its transcription is partially controlled by p53.[8][9] There is evidence that VISTA can act as both a ligand[10] and a receptor[11] on T cells to inhibit T cell effector function and maintain peripheral tolerance.[5][8]

Clinical significanceEdit

VISTA is produced at high levels in tumor-infiltrating lymphocytes, such as myeloid-derived suppressor cells and regulatory T cells, and its blockade with an antibody results in delayed tumor growth in mouse models of melanoma[12] and squamous cell carcinoma.[13]

Monocytes from HIV-infected patients produce higher levels of VISTA compared to uninfected individuals. The increased VISTA levels correlated with an increase in immune activation and a decrease in CD4-positive T cells.[14]

As a drug targetEdit

There is an ongoing cancer immunotherapy clinical trial for a monoclonal antibody targeting VISTA in advanced cancer.[15] Preliminary results of the phase I clinical trial show good safety tolerance and anti-cancer activity in patients with advanced tumours.[16] Another ongoing clinical trial involves a small molecule that antagonizes the programmed death-ligands 1 and 2 (PD-L1 and PD-L2), and VISTA pathways in patients with advanced solid tumors or lymphomas.[17]

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License
.